Non-inferiority of iPragliflozin and metformin on glucose metabolism, pleiotropic effects and safety in type2 diabetes

Non-inferiority of iPragliflozin and metformin on glucose metabolism, pleiotropic effects and safety in type2 diabetes - Effects of iPragliflozin on glucose metabolism and pleiotropic effects

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018979

Enrollment

Registered

2015-09-11

Start date

2014-11-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Ipragliflozin 50 mg/day (6months) Metformin 750mg 3X/day(4days), 1500 mg 3X/day(5 days), 2250mg 3X/day(6months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Diagnosed as type 2 diabetes (2)20=<informed conscent age<75 (3)22.0=<BMI (4) With estimated glomerular function >= 60 ml/min/1.73m2 (5)Subjects who treatment without SGLT2 inhibitors and biguanide (6)Subjects who give consent document about participation in the clinical study

Exclusion criteria

Exclusion criteria: (1) With diabetic ketoacidosis, diabetic coma and type 1 diabetes (2) With infection (3)Has arteriosclerotic disease (myocardial infarction, stroke and so on) and history of them (4) Heavy use of alcohol (5) Considered as inadequate by the investigator

Design outcomes

Primary

Measure	Time frame
Changes in glucose metabolism at 14days after treatment	—

Secondary

Measure	Time frame
(1) Changes in the variables listed below. 1-lipid profile 2-bome metabolism 3-renal function 4-urinanalysis (2) safety	—

Countries

Japan

Contacts

Public ContactHiroko Mori

University of Occupational and Environmental Health First Department of Internal Medicine, School of Medicine

morihiro@med.uoeh-u.ac.jp+8100936031611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026